Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials
Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript
Strong Buy Rating for Chimerix on Robust Financials and Promising Drug Pipeline
Chimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Chimerix's Strong Financials and Promising ONC201 Developments Merit Buy Rating
Earnings Call Summary | Chimerix(CMRX.US) Q1 2024 Earnings Conference
The following is a summary of the Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript:Financial Performance:The balance sheet at the end of March 2024 reported a $188.2 million available capital wi
Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript
Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript
Chimerix Releases Updated Corporate Presentation for Investors
Chimerix (CMRX.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $283,000, with an expected value of $50,000; earnings per share of -$0.25, previous value of -$0.24, and expected value of -$0.21.
Chimerix (CMRX.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $283,000, with an expected value of $50,000; earnings per share of -$0.25, previous value of -$0.24, and expected value of -$0.21.
Chimerix Expects Dordaviprone Interim Overall Survival Data In 2025 And Final OS Data In 2026
Dordaviprone is an oral, first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP.
Chimerix Q1 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 4.17 percent decrease over losses of $(0.24) pe
Chimerix 1Q Rev $0.00 >CMRX
Chimerix 1Q Rev $0.00 >CMRX
Press Release: Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update -- Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studi
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards
We Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully
Chimerix Board Changes: Machado Resigns, Kozin Appointed
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), DENTSPLY SIRONA (XRAY) and Karuna Therapeutics (KRTX)
HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
HC Wainwright & Co. analyst Edward White reiterates Chimerix (NASDAQ:CMRX) with a Buy and maintains $11 price target.
No Data